Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge.
One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Venous blood sampling prior to CCTA. | In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Venous blood sampling prior to CCTA. | Biological |
|
| Measure | Description | Time Frame |
|---|---|---|
| Data registration of patients undergoing CCTA and given written informed consent. | 15 years. | |
| To detect these patients for cardiovascular disease and Long term CV outcome (MACE). | 15 years. |
| Measure | Description | Time Frame |
|---|---|---|
| The relationship of novel blood biomarkers with CCTA findings. | 15 years. | |
| The predictive value of these biomarkers to predict CAD in patients undergoing CCTA. | 15 years. | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients referred from the Cardiology clinic for routine CCTA for diagnostic purposes, will be included in this study, after given written informed consent.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bas Kietselaer, MD, PhD | Contact | +31433871587 | b.kietsealer@mumc.nl | |
| Sibel Altintas, MD | Contact | +31433881232 | s.altintas@mumc.nl |
| Name | Affiliation | Role |
|---|---|---|
| Harry J Crijns, MD, PhD | Maastricht University Medical Center | Study Chair |
| Bas Kietselaer, MD, PhD | Maastricht University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maastricht University Medical Center | Recruiting | Maastricht | Limburg | 6202AZ | Netherlands |
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| The prognostic value of these biomarkers (in combination) to predict MACE. |
| 15 years. |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |